Lupin Limited Earnings Summary — Q1 FY2027
Lupin Reports 16% YoY Growth in Consolidated Net Profit for Q1 FY27
Quarterly Business Intelligence
AI Quarterly Scorecard™
Computed deterministically from the last 10 reported quarters.
Quarterly Business Momentum
- Revenue has increased for 6 consecutive quarters.
- Revenue of ₹8,277 Cr is 32.0% higher year-on-year.
- Revenue has compounded at 25.5% annualised over the last 10 quarters.
- Revenue is at its highest level in 10 quarters.
- Net profit of ₹1,415 Cr is 16.1% above the same quarter last year.
- Profit growth is trailing revenue growth this quarter.
- Net profit has compounded at 83.9% annualised across the period.
- Operating margin stands at 29.6% in Q1 FY2027.
- Operating margin expanded by 204 bps year-on-year.
- Over the last two years operating margin has expanded by 743 bps.
- PBT margin is 24.4%.
- Expense growth of 28.3% remained below revenue growth of 32.0%.
- Operating profit of ₹2,450 Cr is 41.8% higher year-on-year.
- Operating leverage continues to improve.
- 6 of the last 6 measured quarters delivered year-on-year revenue growth.
- Overall quarterly business momentum scores 80/100 (Strong) on the latest 10 quarters.
- Business momentum remains positive heading into the next quarter.
Quarterly Financials
Last 10 Reported Quarters • All figures in ₹ Crore • Margins in %
| Metric | Trend | Latest Q1 FY2027 | Q4 FY2026 | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | Improving | 8,277 | 7,475 | 7,168 | 7,048 | 6,268 | 5,667 | 5,768 | 5,673 | 5,600 | 4,961 |
| Expenses | Improving | 5,827 | 4,989 | 4,906 | 4,706 | 4,541 | 4,346 | 4,412 | 4,332 | 4,359 | 3,964 |
| Operating Profit | Improving | 2,450 | 2,486 | 2,262 | 2,341 | 1,727 | 1,321 | 1,356 | 1,340 | 1,241 | 997 |
| Operating Margin | Improving | 29.6% | 33.3% | 31.6% | 33.2% | 27.6% | 23.3% | 23.5% | 23.6% | 22.2% | 20.1% |
| Other Income | Volatile | 130 | 9 | -312 | 90 | 79 | 57 | 54 | 42 | 68 | 29 |
| Interest | Improving | 110 | 120 | 115 | 108 | 92 | 89 | 67 | 71 | 68 | 71 |
| Depreciation | Accelerating | 453 | 447 | 313 | 317 | 299 | 393 | 271 | 257 | 248 | 457 |
| Profit Before Tax | Strong Uptrend | 2,017 | 1,928 | 1,522 | 2,007 | 1,416 | 896 | 1,071 | 1,055 | 993 | 498 |
| Tax | Strong Uptrend | 600 | 459 | 342 | 522 | 194 | 113 | 212 | 195 | 187 | 129 |
| Net Profit | Improving | 1,415 | 1,460 | 1,176 | 1,478 | 1,219 | 773 | 855 | 853 | 801 | 359 |
| Net Margin | Improving | 17.1% | 19.5% | 16.4% | 21.0% | 19.4% | 13.6% | 14.8% | 15.0% | 14.3% | 7.3% |
Key Takeaways
- Consolidated revenue surged 32% YoY to ₹82,768.9 million, driven by strong performance in the core pharmaceuticals segment.
- Net profit grew 16% YoY to ₹14,169.8 million, despite a slight sequential dip from Q4 FY26 due to higher tax expenses.
- The company concluded the acquisition of VISUfarma B.V., Netherlands, on April 1, 2026, for a total consideration of ₹20,902.7 million.
- Lupin settled a significant antitrust dispute in the U.S. for ₹2,654.1 million (USD 30.0 million) during the quarter without admitting liability.
- Finance costs remained elevated at ₹1,096.4 million, though slightly down from the preceding quarter.
- Deferred tax credits of ₹3,840.1 million significantly supported the bottom line during the quarter.
- Segmental performance shows Pharmaceuticals contributing 99.5% of total revenue with healthy margins.
Management Guidance
Management is focusing on transitioning the business from a recovery phase to a high-growth compounding phase, emphasizing complex generics, respiratory therapies, and biosimilars.
Sentiment Shift
Improving
The business has transitioned from margin compression to a structurally stronger healthcare enterprise with record-high capital efficiency.
Outlook
The outlook remains strong as the company optimizes its product mix in the US and maintains a dominant position in the Indian chronic market, supported by a V-shaped margin recovery.
From the Annual Report (Key Quotes)
“The company and its subsidiary are exposed to multiple civil lawsuits... litigation are often resolved through settlement agreements.”
“During the quarter ended June 30, 2026, acquisition of wholly owned subsidiary VISUfarma B.V. was concluded.”
“Lupin has demonstrated a significant turnaround in its business quality over the last three fiscal years.”
Official Quarterly Documents
Ask AI about this quarter
This summary is AI-generated from Lupin Limited's latest quarterly filing and earnings call. For informational purposes only — not investment advice.